1-4 of 4
Timothy P. Hughes
Close
Sort by
Journal Articles

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia

Yazad D. Irani, Chung H. Kok, Jade Clarson, Naranie Shanmuganathan, Susan Branford, David T. Yeung, David M. Ross, Timothy P. Hughes, Agnes S. M. Yong
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2364–2374.
https://doi.org/10.1182/bloodadvances.2022008854
Published: 2023
Includes: Supplemental data
Journal Articles

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

Clinical Trials & Observations
Chung H. Kok, David T. Yeung, Liu Lu, Dale B. Watkins, Tamara M. Leclercq, Phuong Dang, Verity A. Saunders, John Reynolds, Deborah L. White, Timothy P. Hughes
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1610–1621.
https://doi.org/10.1182/bloodadvances.2019000195
Published: 2019
Includes: Supplemental data
Journal Articles

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI

Clinical Trials & Observations
Naranie Shanmuganathan, Susan Branford, Timothy P. Hughes, Devendra Hiwase
Journal: Blood Advances
Blood Adv (2019) 3 (3): 370–374.
https://doi.org/10.1182/bloodadvances.2018027516
Published: 2019
Includes: Supplemental data
Journal Articles

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure

Clinical Trials & Observations
Justine E. Marum, David T. Yeung, Leanne Purins, John Reynolds, Wendy T. Parker, Doris Stangl, Paul P. S. Wang, David J. Price, Jonathan Tuke, Andreas W. Schreiber, Hamish S. Scott, Timothy P. Hughes, Susan Branford
Journal: Blood Advances
Blood Adv (2017) 1 (18): 1369–1381.
https://doi.org/10.1182/bloodadvances.2017006825
Published: 2017
Includes: Supplemental data